Acumyn’s AQUA platform has the power to improve the efficiency and workflows in radiation therapy departments—including providing automated daily quality assurance (QA) for radiation therapy clinics and hospitals. AQUA can directly interface with automated quality control software and hardware to minimize the burden of QA activities, and Standard Imaging has become one of the first radiation calibration instrument manufacturers to integrate their technology—the QA BeamChecker Plus—with the AQUA platform to realize these benefits.
“We are pleased to welcome Standard Imaging to the AQUA ecosystem as an early OEM partner sharing our vision to deliver an automated QA platform to oncology clinics worldwide,” says Ferhan Bulca, CEO of Acumyn.
“We believe a unified and integrated approach to QA data sharing has the potential to improve efficiency and usefulness in patient care. Products like AQUA and Standard Imaging’s new QA Pilot software are efficient data management solutions for the future of radiation therapy’s knowledge based QA platforms,” says Edward Neumueller, CEO of Standard Imaging, Inc.
Under an exclusive global agreement AQUA is sold and marketed by Elekta who will be demonstrating this vendor-neutral system on their booth at the 3rd ESTRO Forum in Barcelona, Spain in April 2015. Demonstrations will highlight AQUA’s integration with Elekta Linacs, the QA BeamChecker Plus as well as other QA devices and radiation therapy hardware.
Acumyn is the Ontario-based company behind the development of AQUA, an end-to-end system for managing department-level quality assurance workflows and scheduling in radiation therapy that provides a software link between the disparate systems in a department. Standard Imaging is a US-based leading provider of radiation calibration instruments used in radiation therapy and other medical fields.
Acumyn’s AQUA platform has the power to automate quality control software and hardware, which will improve efficiency and workflows in radiation therapy departments—including providing automated morning QA for radiation therapy clinics and hospitals. PTW has become one of the first dosimeter manufacturers to integrate their technology—PTW’s network-capable UNIDOSwebline universal dosimeter—with the AQUA platform to realize these benefits.
Ferhan Bulca, CEO of Acumyn, says “We believe that customers have been looking for an integrated and automated tool for routine QC, and this collaboration with PTW and their connected dosimeter is a giant step toward making those hopes and aspirations a reality.”
Bernd Allgaier, Head of Product Management at PTW quote “Our UNIDOSwebline has been the dosimeter of choice around the world from a performance standpoint, and we’re proud that including modern network features can enable exciting new applications like this integration with AQUA to automate functions within a busy clinic.-”
Under an exclusive global agreement AQUA is sold and marketed by Elekta who will be demonstrating this vendor-neutral system on their booth at the 3rd ESTRO Forum in Barcelona, Spain in April 2015. Demonstrations will highlight AQUA’s integration with Elekta Linacs, the UNIDOSwebline dosimeter as well as other QA devices and radiation therapy hardware.
Acumyn is the Ontario-based company behind the development of AQUA, an end-to-end system for managing department-level quality assurance workflows and scheduling in radiation therapy that provides a software link between the disparate systems in a department. PTW is a German-based leading provider of dosimetry and quality control equipment used in radiation therapy and other medical fields.
[UHN article: UHN Research ]
University Health Network (UHN) and its spin-off company, Acumyn Inc., have secured an exclusive development and global distribution agreement with one of the world’s biggest radiation therapy companies, Elekta Ltd, to bring to market UHN’s AQUA quality management system software for radiation therapy clinics. The agreement will see UHN’s award-winning AQUA platform developed into a marketable product by Acumyn and then offered to cancer clinics around the world by Elekta, a leading manufacturer of linear accelerators for cancer treatment.
AQUA is a comprehensive software platform that coordinates and centralizes all of the quality assurance tests that need to be performed in a radiotherapy clinic, helping to manage the complexity of these testing requirements.
“AQUA fills a big gap that customers have today. A linear accelerator and associated devices need to be calibrated and maintained on a regular basis. AQUA provides a software link between all the disparate systems and manages the workload, scheduling and reporting of routine QA tasks,” says Dee Mathieson, Senior Vice President, Oncology Business Line Management at Elekta.
In use for the past two years in Toronto at UHN’s Princess Margaret Cancer Centre, a top-five global cancer hospital, AQUA is a vendor-neutral product that has successfully connected, calibrated and managed over 20 of UHN’s cancer therapy machines. It was originally developed and clinically implemented by Drs. David Jaffray and Daniel Létourneau, of UHN’s Princess Margaret Cancer Center and TECHNA Institute.
“The current model for quality control (QC) in radiation oncology is to perform basic QC tests daily to detect machine performance while higher accuracy QC tests are performed less frequently (e.g. monthly) due to their time consuming nature,” says Dr Daniel Létourneau, Associate Head of Physics at the Princess Margaret Cancer Center. “With AQUA, high accuracy QC tests can now be performed daily in order to assess true machine performance and optimize the accuracy of radiation oncology treatment delivery.”
Acumyn Inc. was spun out of UHN with the purpose of bringing AQUA to market.
“We are delighted to have solidified this commercial relationship and cooperation with Elekta which allowed Acumyn to complete its incubation phase. It is an important milestone in terms of commercializing UHN technologies and creating high-quality local jobs and globally-significant healthcare products,” says Mark Taylor, UHN’s Director of Commercialization, Techna.
“Securing global distribution for a product while it is still in development is a huge achievement,” says Dr. Ferhan Bulca, Acumyn’s CEO. “It speaks to the clear need for a product like AQUA to simplify and eliminate human error and ensure that cancer therapy components are aligned to deliver the right amount of radiation to the right areas of the body.”
Elekta will begin piloting Acumyn’s market-ready version of AQUA starting in January 2015, before adding it to its commercial portfolio in April 2015.
For more information:
Mark Taylor, Director of Commercialization, Techna, UHN Technology Development & Commercialization
Dr. Ferhan Bulca, CEO Acumyn Inc.
T: (416) 854-6599; E: firstname.lastname@example.org